Overview

Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high risk for PONV who require combination therapy. This study sought to identify the optimal dose of haloperidol that could be combined with dexamethasone without adverse effects in high-risk PONV patients receiving intravenous patient-controlled anesthesia (IV PCA) after gynecological laparoscopic surgery.
Phase:
N/A
Details
Lead Sponsor:
The Catholic University of Korea
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Haloperidol
Haloperidol decanoate